Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
FRA:I54's 9-Day RSI is ranked worse than 78.34% of 1422
companies
in the Biotechnology industry
Industry Median: 43.945
vs FRA:I54: 54.38
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Biocytogen Pharmaceuticals (Beijing) Co 9-Day RSI Related Terms
FRA:I54 vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocytogen Pharmaceuticals (Beijing) Co 9-Day RSI vs Biotechnology Industry
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) has a 9-Day RSI of 54.38 as of Jul. 23, 2026. According to the industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #1114 out of 1422 companies in the Biotechnology industry, placing it in the top 78.3%.
Is Biocytogen Pharmaceuticals (Beijing) Co's 9-Day RSI too high?
Biocytogen Pharmaceuticals (Beijing) Co's current 9-Day RSI is 54.38. The Biotechnology industry median 9-Day RSI is 43.95. Biocytogen Pharmaceuticals (Beijing) Co's value of 54.38 is 23.7% above this industry median. Based on the distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #1114 out of 1422 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #1114 out of 1422 companies for 9-Day RSI. This places Biocytogen Pharmaceuticals (Beijing) Co in the lower half of its industry. The industry median 9-Day RSI is 43.95. Biocytogen Pharmaceuticals (Beijing) Co's value of 54.38 is 23.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 43.95, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biocytogen Pharmaceuticals (Beijing) Co's current 9-Day RSI of 54.38 is 23.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 43.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocytogen Pharmaceuticals (Beijing) Co's current 9-Day RSI is 54.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.53, compared to a current price of €5.70 — trading 61.5% above its estimated fair value. The current 9-Day RSI is 54.38 and 23.7% above the Biotechnology industry median of 43.95. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54), the current 9-Day RSI is 54.38 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Overvalued in 2026?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued.
The current stock price of €5.70 is trading 61.5% above its estimated GF Value™ of €3.53.
GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.
Key valuation signals for FRA:I54:
9-Day RSI: 54.38
GF Value™: €3.53 vs. price of €5.70 (61.5% above fair value)
Industry Position: 23.7% above the Biotechnology median (#1114 of 1422)
No single metric tells the full story. See the FRA:I54 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocytogen Pharmaceuticals (Beijing) Co Business Description
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
79GF Score
Get the complete analysis for FRA:I54
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:I54 has been successfully added to your 
